Back to results

Open-Label, Non-Randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/ Ethnicity on Treosulfan Pharmacokinetics in Patients with AML or MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Objective

To determine an appropriate safe dose of treosulfan and to assess the influence of moderate renal impairment on primary treosulfan pharmacokinetics (PK) parameters

Protocol #

MC-FLUDT-19-PK

Trial Phase:

Phase I

Principal Investigator:

Clark, William

Cancer Type
  • Myeloid and Monocytic Leukemia
  • Other Hematopoietic
Study Site
  • Virginia Commonwealth University

Participants with AML or MDS who qualify for treosulfan-based conditioning treatment, indicated for alloHSCT.
Have available matched-related, matched-unrelated, haploidentical, or a mismatched unrelated donor
Age 18-80 years

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Other
  • Research Study Team Kristin Lantis, MSN, RN, CCRP
    Phone: +1 804-828-2177
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: